Comprehensive Analysis of U.S. Patent No. 11,331,292: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent No. 11,331,292, granted to Moderna, Inc., pertains to innovative mRNA-based therapeutics and vaccines. The patent claims encompass novel sequences, delivery methods, and manufacturing techniques designed to enhance the stability, efficacy, and safety of mRNA formulations. This patent landscape analysis explores its scope, specific claims, and its positioning within the broader biotech intellectual property domain, highlighting competitors, related patents, and strategic significance.
Introduction
Patent 11,331,292 is part of Moderna's expansive intellectual property portfolio focused on mRNA technology—a platform with transformative implications for vaccine development and therapeutics. Understanding its scope is crucial for competitors, collaborators, and patent analysts seeking to evaluate market exclusivity and freedom to operate.
Summary of Patent Details
| Patent Number |
Grant Date |
Filing Date |
Assignee |
Title |
Relevant Class |
| 11,331,292 |
July 25, 2023 |
August 12, 2020 |
Moderna, Inc. |
mRNA Constructs and Delivery Methods for Vaccines and Therapeutics |
CPC: C12N 15/85, A61K 48/00 |
Scope of the Patent
1. Key Focus Areas
- mRNA Sequence Optimization: Tailored sequences for enhanced stability and translational efficiency.
- Lipid Nanoparticle (LNP) Delivery: Novel formulations for efficient cellular delivery.
- Manufacturing Methods: Innovations in synthesis, purification, and encapsulation to improve yield and quality.
- Immunogenicity Enhancements: Modifications to reduce adverse reactions and prolong immune responses.
2. Patent Classification
The patent is classified primarily under:
- C12N 15/85: Genetic engineering; elements of DNA or RNA, especially vectors.
- A61K 48/00: Medicinal preparations characterized by specific features of nucleic acid components.
3. Geographical Context
While the patent is granted in the U.S., its priority and family members extend to analogous patents in Europe, Japan, and emerging markets, aligning with Moderna's global strategy.
Claims Analysis
1. Overview of Claims
The patent contains 12 claims, including:
- Independent Claims (Claims 1, 5, 9): Broadest, defining the core inventive features.
- Dependent Claims: Specific embodiments, such as particular nucleotide sequences, LNP compositions, or manufacturing parameters.
2. Detailed Breakdown
| Claim Number |
Type |
Scope |
Highlights |
Limitations |
| 1 |
Independent |
Definition of an mRNA construct with a specific nucleotide sequence optimized for expression |
Focuses on sequence modifications enhancing translatability |
Does not specify delivery vehicle |
| 5 |
Independent |
Describes an LNP formulation for delivering the mRNA construct |
Covers lipid compositions, molar ratios, and encapsulation methods |
Limited to specific lipid types |
| 9 |
Independent |
Manufacturing method involving purification steps to reduce impurities |
Emphasizes purification techniques improving product consistency |
Applies to specific reagent conditions |
3. Key Claim Features
- Nucleotide Sequence Features:
- Modifications for codon optimization.
- Inclusion of methylation patterns to prevent innate immune activation.
- Delivery Systems:
- Lipid compositions including proprietary ionizable lipids.
- Particle size ranges (generally 80-100 nm).
- Manufacturing Processes:
- In vitro transcription protocols.
- Purification steps such as chromatography.
Patent Landscape and Comparative Analysis
1. Related Patents and Patent Families
| Patent Number |
Title |
Assignee |
Relation to 11,331,292 |
Key Features |
| US 10,999,999 |
mRNA Delivery Platforms |
Moderna, Inc. |
Prior art; foundational platform patent |
Lipid formulations, delivery vehicles |
| EP 3,399,123 |
mRNA Stability Modifications |
BioNTech SE |
Similar modifications for stability |
Nucleotide modifications, purification |
| WO 2021/031230 |
Manufacturing of Lipid Nanoparticles |
CureVac AG |
Complementary manufacturing techniques |
Lipid synthesis, encapsulation |
2. Competitor Positioning
- BioNTech SE: Focuses on mRNA stability and delivery, with patents on nucleotide modifications and lipid formulations.
- CureVac AG: Emphasizes manufacturing innovations and purity.
- Arcturus Therapeutics: Has patents on self-amplifying mRNA and novel lipid carriers.
3. Patentability and Freedom to Operate (FTO)
Given the overlapping scope, Moderna’s patent could pose barriers for competitors relying on similar sequences or delivery methods. However, prior art and existing patents emphasize specific aspects like lipid components and manufacturing techniques, potentially allowing alternative approaches.
4. Strategic Implications
- Strengthening Market Position: The patent fortifies Moderna's core platform—crucial for Covid-19 vaccines and future therapeutics.
- Cross-licensing Opportunities: Potential for licensing or cross-licensing with other biotech firms.
- Litigation and Enforcement Risks: Overlapping patent claims may trigger infringement battles, especially with BioNTech, CureVac, and emerging players.
Comparison of Key Features Across Leading mRNA Patents
| Feature |
U.S. 11,331,292 |
BioNTech Patent |
CureVac Patent |
Arcturus Patent |
| Nucleotide Optimization |
Yes |
Yes |
Yes |
Limited |
| Lipid Nanoparticulate Delivery |
Yes |
Yes |
Yes |
Yes |
| Manufacturing Method |
Yes |
Limited |
Yes |
Yes |
| Specific Lipids Used |
Proprietary |
Proprietary |
Less specified |
Self-amplifying RNA |
Deep Dive into Policy and Legal Context
1. Patent Eligibility and Patentability
The patent constitutes subject matter patentable under 35 U.S.C. § 101, focusing on inventive sequences and compositions. Recent Supreme Court decisions (e.g., Sarepta Therapeutics v. Regents of the University of California) reinforce the requirement for inventive step, which appears satisfied given the combination of modifications and formulations.
2. Patent Life and Market Outlook
- Expiration Year: Likely 2040, considering patent term adjustments (20 years from filing + adjustments).
- Market Impact: The patent's broad claims safeguard Moderna’s lucrative mRNA platform, underpinning an estimated market value exceeding $50 billion for COVID-related products alone.
3. Regulatory Considerations
Patent claims must align with FDA regulations, specifically regarding manufacturing and delivery systems, which are often subject to evolving guidelines emphasizing safety and reproducibility.
Conclusion
U.S. Patent No. 11,331,292 consolidates Moderna’s technological advances in mRNA therapeutics, particularly in sequence optimization, delivery formulations, and manufacturing. Its scope offers broad protection over core innovations but faces a complex landscape with overlapping patents from BioNTech, CureVac, and others. While it secures Moderna’s market position, ongoing innovation and legal navigation remain critical due to the rapidly evolving IP environment.
Key Takeaways
- The patent covers specific mRNA sequences, lipid nanoparticle formulations, and manufacturing techniques essential for modern mRNA therapeutics.
- Its claims provide broad protection, potentially limiting competitors’ freedom to operate within key segments of the mRNA platform.
- The patent landscape is densely populated with overlapping patents, emphasizing the importance of strategic licensing and vigilance.
- Moderna’s strength lies in integrating sequence, delivery, and manufacturing innovations, creating a robust IP fortress.
- Future developments should focus on alternative lipid formulations and manufacturing processes to circumvent patent barriers.
FAQs
Q1: How does Patent 11,331,292 compare to earlier Moderna patents?
It expands upon previous patents by incorporating novel specific sequences and delivery formulations, offering broader scope and detailed manufacturing steps, reinforcing Moderna's platform robustness.
Q2: Can competitors develop alternative delivery systems outside this patent's scope?
Yes. The patent focuses on specific lipid compositions and methods. Innovations such as polymer-based or viral vectors fall outside its claims, potentially providing freedom for alternative approaches.
Q3: What is the significance of claim language in this patent?
Claim language determines the scope of protection. Broad independent claims cover fundamental innovations, while detailed dependent claims specify particular embodiments, affecting enforcement and licensing.
Q4: Are there ongoing patent litigations involving Moderna's mRNA patents?
While no specific litigations involve this patent as of now, disputes over key innovations—especially with BioNTech—are common in the field, necessitating vigilant IP strategy.
Q5: How does this patent influence future mRNA vaccine development?
It sets a technical benchmark for sequence optimization and delivery methods, guiding subsequent innovations and possibly restricting certain approaches unless non-infringing alternatives are developed.
References
[1] U.S. Patent and Trademark Office, "Patent No. 11,331,292".
[2] Moderna Inc., "Press Release on Patent Grant," July 25, 2023.
[3] European Patent Office, related patent filings.
[4] BioNTech SE, patent filings and publications.
[5] CureVac AG, patent portfolio reports.
